Arbutus Biopharma Corp to Discuss New Data at EASL ILC 2022 Transcript
Good morning, ladies and gentlemen. Thank you for standing by, and welcome to the EASL Clinical Data Update Conference Call. (Operator Instructions) Please be advised that today's conference may be recorded. (Operator Instructions)
I would now like to turn the conference over to your speaker host today, Lisa Caperelli. Please go ahead.
Thank you, Olivia. Good morning, everyone, and thank you for joining our webcast. As a reminder, we will be presenting slides on this webcast, and you can access the webcast via the Investors section of our website at arbutusbio.com.
With me today from the Arbutus executive team are Bill Collier, President and Chief Executive Officer; Dr. Gaston Picchio, Chief Development Officer; Dr. Mike Sofia, Chief Scientific Officer; Mike McElhaugh, Chief Business Officer; and David Hastings, Chief Financial Officer.
Bill will begin with a quick summary of the EASL presentations. Dr. Mike Sofia is standing in for Gaston, who has laryngitis, and will walk
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |